Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · IEX Real-Time Price · USD
5.56
-0.01 (-0.18%)
At close: Jul 19, 2024, 4:00 PM
5.57
+0.01 (0.18%)
Pre-market: Jul 22, 2024, 7:52 AM EDT
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $191.41M in the twelve months ending March 31, 2024, with 30.37% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $50.30M with 46.19% year-over-year growth. In the year 2023, Aurinia Pharmaceuticals had annual revenue of $175.51M with 30.95% growth.
Revenue (ttm)
$191.41M
Revenue Growth
+30.37%
P/S Ratio
4.15
Revenue / Employee
$638,023
Employees
300
Market Cap
795.19M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
Dec 31, 2018 | 463.00K | 45.00K | 10.77% |
Dec 31, 2017 | 418.00K | 245.00K | 141.62% |
Dec 31, 2016 | 173.00K | -62.00K | -26.38% |
Dec 31, 2015 | 235.00K | -43.00K | -15.47% |
Dec 31, 2014 | 278.00K | -691.00K | -71.31% |
Dec 31, 2013 | 969.00K | -5.16M | -84.18% |
Dec 31, 2012 | 6.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Clover Health Investments | 1.85B |
Cytek Biosciences | 200.79M |
Atrion | 176.67M |
OrthoPediatrics | 161.83M |
Simulations Plus | 66.98M |
Abivax | 5.13M |
Dianthus Therapeutics | 2.26M |
AUPH News
- 3 days ago - Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 - Business Wire
- 10 days ago - ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM - Business Wire
- 20 days ago - Aurinia to Participate in Upcoming Investor Healthcare Conferences - Business Wire
- 5 weeks ago - Aurinia Announces 2024 Annual General Meeting Results - Business Wire
- 6 weeks ago - Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 - Business Wire
- 6 weeks ago - Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce - Business Wire
- 6 weeks ago - Aurinia Provides Update on Proxy Statement - Business Wire
- 7 weeks ago - Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf - Business Wire